Novo Nordisk chief says investors overlook its pipeline beyond the Lilly rivalry
The profile lays out Novo Nordisk's pitch to investors and the patent clock behind it, with no new approvals or price changes announced for the semaglutide drugs patients use.
Novo Nordisk chief executive Mike Doustdar is telling investors they are too focused on the company's competition with Eli Lilly and are underestimating the breadth of Novo's portfolio and pipeline, according to a New York Times profile published September 1 [1].
The profile was reported from New York and from Clayton and Durham, North Carolina, and appeared roughly a year into Doustdar's effort to turn the company around [1]. Novo Nordisk sells Ozempic and Wegovy, both semaglutide, along with Rybelsus, an oral semaglutide. Eli Lilly sells the rival GLP-1 drugs Mounjaro and Zepbound, both tirzepatide [1].
Pills are framed in the piece as Novo's likely second act after the Ozempic injection [1]. The article treats that shift as the company's central bet on what comes after its current injection business, though it does not lay out which oral products, launch dates or study results would carry it [1].
Underneath the strategy argument is a specific piece of investor anxiety: the key US patent on semaglutide expires early in the next decade [1]. That date is the one concrete milestone in the profile, and it sits behind much of the concern the article describes about how long Novo can keep the semaglutide franchise insulated from competition [1].
Other specifics are not yet public. Sales targets, revenue projections, manufacturing figures, oral-candidate launch dates and trial results have not been reported in the profile, and Novo has not disclosed how it plans to handle the patent expiry [1].
Why it matters for patients
The drugs at the center of this debate are the same ones millions of Americans already take. Ozempic, Wegovy and Rybelsus are all semaglutide, while Mounjaro and Zepbound are tirzepatide, so a corporate argument about portfolio breadth is also an argument about the products people are currently prescribed [1].
The patent date matters because patent expiry is generally the point at which generic competitors can enter a market, which can change pricing and supply over time. What that would mean for any individual's cost, insurance coverage or access has not been reported, and no company plan for the period after expiry has been disclosed [1].
Pills as a "second act" is a statement about company strategy, not about what is available now. The profile does not announce a new approval, a new indication or a coverage change for any semaglutide product, and it does not report data that would support one [1]. For patients tracking whether an oral option might someday replace an injection, the practical timeline remains unstated.
It is also worth separating the competitive framing from the clinical one. The profile describes an investor narrative about Novo versus Eli Lilly [1]. It does not report new head-to-head results between semaglutide and tirzepatide, and it does not suggest that either company's stock story changes how a given drug performs or how it should be used [1].
What happens next
The only dated milestone in the account is the expiration of the key US semaglutide patent early in the next decade [1]. The profile was published September 1, 2026 [1]. No date has been reported for an oral product launch, a pipeline readout or any change to the semaglutide franchise, and Novo Nordisk has not disclosed a timeline for addressing the patent expiry [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.